Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Since, Viking's clinical data remain strong, and the company aims to launch a phase 3 trial for the injectable version of VK2735 in the second quarter. It's also advanced an oral version, starting a ...

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

For those looking for Zepbound (tirzepatide) online, our expert team has vetted the best places to buy this prescription-only weight loss drug. Plus, learn more about shortages, drug effectiveness ...

Novo Nordisk (NYSE: NVO) shareholders know all about the ups and downs of pharmaceutical stock investing. From the beginning ...

Four-star-rated analyst Daniel Grosslight at Citi reiterated his Sell rating on Hims & Hers Health (HIMS) stock yesterday, ...

Meanwhile, tirzepatide-treated patients saw their weight ... of the CAR-T therapy it partners with 2seventy bio, agreeing to buy the biotech for around $286m. Bryan Hill, life sciences chief ...

Tirzepatide was previously shown to provide sustained weight reductions in adults with obesity. New longer-term findings in adults with both obesity and prediabetes are summarized in a short video.